Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hedy Teppler

Showing results (11-20 of 64) with videos related to

Pageof 7
Sort By:
Infectious Diseases in Obstetrics and Gynecology|July 4, 2003
Ertapenem once a day versus piperacillin-tazobactam every 6 hours for treatment of acute pelvic infections: a prospective, multicenter, randomized, double-blind studySubir Roy, Iliana Higareda, Edith Angel-Muller, et al.
The Journal of Antimicrobial Chemotherapy|May 20, 2004
Safety and tolerability of ertapenemHedy Teppler, Richard M Gesser, Ian R Friedland, et al.
Cancer|December 15, 2005
Efficacy of caspofungin against invasive Candida or invasive Aspergillus infections in neutropenic patientsRobert Betts, Axel Glasmacher, Johan Maertens, et al.
The Pediatric Infectious Disease Journal|October 25, 2021
A Health Literate Patient-focused Approach to the Redesign of the Raltegravir (ISENTRESS) Pediatric Kit and Instructions for UseAlexander Mills, Laurie Myers, Casey Raudenbush, et al.
AIDS (London, England)|February 15, 2021
Efficacy, safety and central nervous system effects after switch from efavirenz/tenofovir/emtricitabine to doravirine/tenofovir/lamivudineMark Nelson, Alan Winston, Andrew Hill, et al.
CPT: Pharmacometrics & Systems Pharmacology|June 20, 2019
Maternal-Neonatal Raltegravir Population Pharmacokinetics Modeling: Implications for Initial Neonatal DosingJos Lommerse, Diana Clarke, Thomas Kerbusch, et al.
AIDS (London, England)|December 20, 2007
Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phaseJohn M Murray, Sean Emery, Anthony D Kelleher, et al.
AIDS (London, England)|April 28, 2011
Clinical efficacy of raltegravir against B and non-B subtype HIV-1 in phase III clinical studiesJürgen K Rockstroh, Hedy Teppler, Jing Zhao, et al.
Open Forum Infectious Diseases|May 9, 2017
Influence of Sex/Gender and Race on Responses to Raltegravir Combined With Tenofovir-Emtricitabine in Treatment-Naive Human Immunodeficiency Virus-1 Infected Patients: Pooled Analyses of the STARTMRK and QDMRK StudiesKathleen Squires, Linda-Gail Bekker, Christine Katlama, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 18, 2020
Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (TDF) Versus Efavirenz/Emtricitabine/TDF in Treatment-naive Adults With Human Immunodeficiency Virus Type 1 Infection: Week 96 Results of the Randomized, Double-blind, Phase 3 DRIVE-AHEAD Noninferiority TrialChloe Orkin, Kathleen E Squires, Jean-Michel Molina, et al.
Pageof 7

Showing results (11-20 of 64) with videos related to

Sort By:
Pageof 7
Infectious Diseases in Obstetrics and Gynecology|July 4, 2003
Ertapenem once a day versus piperacillin-tazobactam every 6 hours for treatment of acute pelvic infections: a prospective, multicenter, randomized, double-blind studySubir Roy, Iliana Higareda, Edith Angel-Muller, et al.
The Journal of Antimicrobial Chemotherapy|May 20, 2004
Safety and tolerability of ertapenemHedy Teppler, Richard M Gesser, Ian R Friedland, et al.
Cancer|December 15, 2005
Efficacy of caspofungin against invasive Candida or invasive Aspergillus infections in neutropenic patientsRobert Betts, Axel Glasmacher, Johan Maertens, et al.
The Pediatric Infectious Disease Journal|October 25, 2021
A Health Literate Patient-focused Approach to the Redesign of the Raltegravir (ISENTRESS) Pediatric Kit and Instructions for UseAlexander Mills, Laurie Myers, Casey Raudenbush, et al.
AIDS (London, England)|February 15, 2021
Efficacy, safety and central nervous system effects after switch from efavirenz/tenofovir/emtricitabine to doravirine/tenofovir/lamivudineMark Nelson, Alan Winston, Andrew Hill, et al.
CPT: Pharmacometrics & Systems Pharmacology|June 20, 2019
Maternal-Neonatal Raltegravir Population Pharmacokinetics Modeling: Implications for Initial Neonatal DosingJos Lommerse, Diana Clarke, Thomas Kerbusch, et al.
AIDS (London, England)|December 20, 2007
Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phaseJohn M Murray, Sean Emery, Anthony D Kelleher, et al.
AIDS (London, England)|April 28, 2011
Clinical efficacy of raltegravir against B and non-B subtype HIV-1 in phase III clinical studiesJürgen K Rockstroh, Hedy Teppler, Jing Zhao, et al.
Open Forum Infectious Diseases|May 9, 2017
Influence of Sex/Gender and Race on Responses to Raltegravir Combined With Tenofovir-Emtricitabine in Treatment-Naive Human Immunodeficiency Virus-1 Infected Patients: Pooled Analyses of the STARTMRK and QDMRK StudiesKathleen Squires, Linda-Gail Bekker, Christine Katlama, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 18, 2020
Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (TDF) Versus Efavirenz/Emtricitabine/TDF in Treatment-naive Adults With Human Immunodeficiency Virus Type 1 Infection: Week 96 Results of the Randomized, Double-blind, Phase 3 DRIVE-AHEAD Noninferiority TrialChloe Orkin, Kathleen E Squires, Jean-Michel Molina, et al.
Pageof 7